
Sanofi to acquire Blueprint for up to $9.5B
Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint’s research revolves around an enzyme made by a gene called KIT. This “tyrosine kinase” …